A Review of the Clinical Trial Landscape in Psoriasis: An Update for Clinicians.

ABSTRACT: As our understanding of the pathogenesis of psoriasis has evolved over the past two decades, so has the number of treatment options. The introduction of biologic agents targeting specific cytokines in the interleukin (IL)-23/IL-17 pathway has proven successful in promoting skin clearance among patients. However, their use is often limited owing to cost, parenteral administration, and possible reduced efficacy over time. Topical therapies have also seen limited advancement, with agents such as corticosteroids and vitamin D derivatives remaining the mainstay of treatment, despite side effects limiting their long-term use. New therapeutic agents are needed to improve disease management for patients. In this review, we summarize pipeline and recently approved therapies undergoing clinical tria

SUBMITTER: Drakos A 

PROVIDER: S-EPMC9674811 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature